Comparative Pharmacology
Head-to-head clinical analysis: VALACYCLOVIR HYDROCHLORIDE versus XOFLUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALACYCLOVIR HYDROCHLORIDE versus XOFLUZA.
VALACYCLOVIR HYDROCHLORIDE vs XOFLUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valacyclovir hydrochloride is a prodrug of acyclovir. After oral administration, it is rapidly converted to acyclovir, which inhibits viral DNA polymerase, leading to chain termination and inhibition of viral DNA replication.
Baloxavir marboxil is a prodrug that is converted to baloxavir acid, which inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, thereby preventing viral mRNA transcription and replication.
500 mg orally twice daily for recurrent genital herpes; 1 g orally twice daily for herpes zoster; 1 g orally three times daily for herpes simplex encephalitis or immunocompromised patients.
40 mg orally once as a single dose; for patients weighing ≥80 kg, 80 mg orally once as a single dose.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.3 hours in patients with normal renal function; prolonged to 14 hours in renal impairment (CrCl 15–30 mL/min).
The terminal elimination half-life of baloxavir marboxil is approximately 79.1 hours (range 53–107 hours), supporting single-dose therapy for influenza.
Renal excretion: >90% as unchanged drug and inactive metabolite (9-carboxymethoxymethylguanine). Biliary/fecal: <2%.
Baloxavir marboxil is primarily excreted via feces (80.1%) and urine (14.7%) after oral administration, with <1% as unchanged drug in urine.
Category A/B
Category C
Antiviral
Antiviral